台灣臨床試驗主持人資料庫|TPIDB

2017-08-11 - 2020-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Alpha Agents

Condition/Disease

Psoriatic Arthritis
Test Drug

CNTO1959(guselkumab)

Participate Sites
7Sites

Terminated7Sites

黃毓惠

Linkou Chang Gung Medical Foundation

Division of Dermatology

2016-05-01 - 2018-12-14

Phase III

Condition/Disease
Test Drug

Participate Sites
3Sites

Terminated3Sites

劉嘉逸

Linkou Chang Gung Medical Foundation

Division of Psychiatry

2015-09-01 - 2018-12-31

Phase III

Condition/Disease
Test Drug

Participate Sites
6Sites

Terminated6Sites

羅淑芬

Linkou Chang Gung Medical Foundation

Division of Rheumatology

2015-07-01 - 2019-03-31

Phase I

A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients with Advanced Solid Tumours

Condition/Disease

Advanced Solid Tumours
Test Drug

MEDI4736

Participate Sites
3Sites

Not yet recruiting3Sites

陳仁熙

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2015-01-01 - 2017-12-31

Phase III

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Roxadustat for the Treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis

Condition/Disease

Chronic Kidney Disease
Test Drug

Roxadustat

Participate Sites
12Sites

Study ended12Sites

洪振傑

Linkou Chang Gung Medical Foundation

Division of Nephrology

唐德成

Taipei Veterans General Hospital

Division of Nephrology

2018-01-22 - 2019-12-31

Phase III

A Randomized, Double-Blinded, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared with ASA in the Prevention of Stroke and Death in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack

Condition/Disease

Acute Ischemic Stroke or Transient ischaemic attack
Test Drug

BRILINTA

Participate Sites
16Sites

Recruiting15Sites

Study ended1Sites

李宗海

Linkou Chang Gung Medical Foundation

Division of Neurology

林秀芬

Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Neurology

2015-05-01 - 2020-06-11

Phase II

ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group

Condition/Disease

Glioblastoma Multiforme (GBM)
Test Drug

ABT-414

Participate Sites
5Sites

Terminated5Sites

魏國珍

Linkou Chang Gung Medical Foundation

Division of Orthopedics

2015-10-15 - 2020-04-22

Phase III

A Randomized, Placebo Controlled Phase 2b/3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma Multiforme (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification. (Intellance1)

Condition/Disease

Glioblastoma Multiforme (GBM)
Test Drug

ABT-414

Participate Sites
3Sites

Terminated3Sites

魏國珍

Linkou Chang Gung Medical Foundation

Division of Orthopedics

2018-08-31 - 2025-06-30

Phase III

A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

Condition/Disease

Moderate to Severe Atopic Dermatitis
Test Drug

Upadacitinib

Participate Sites
4Sites

Terminated4Sites

黃毓惠

Linkou Chang Gung Medical Foundation

Division of Dermatology

李婉若

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Dermatology

2014-07-01 - 2020-12-31

Phase III

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngeal Carcinoma Patients

Condition/Disease

Advanced Nasopharyngeal Carcinoma
Test Drug

Epstein-Barr virus-specific autologous cytotoxic T lymphocytes

Participate Sites
8Sites

Terminated7Sites

王宏銘

Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

謝清昀

China Medical University Hospital-Taipei

未分科

Search Result

List